Intensity of end-of-life health care and mortality after systemic anti-cancer treatment in patients with advanced lung cancer

Kersti Oselin ( kersti.oselin@regionaalhaigla.ee )
North Estonia Medical Centre  https://orcid.org/0000-0002-3862-3882

Heti Pisarev
Tartu Ulikool

Keit Ilau
Regionaalhaigla

Raul-Allan Kiivet
Tartu Ulikool

Research article

Keywords: Advanced lung cancer, End-of-life care, High intensity care

DOI: https://doi.org/10.21203/rs.3.rs-19211/v3

License: ☒  This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: We aimed to study the mortality and intensity of health care in patients with advanced lung cancer who received systemic anti-cancer treatment (SACT) compared with patients who were not eligible for SACT (no-SACT).

Methods: A retrospective cohort of patients with lung cancer, who were treated at the North Estonia Medical Centre from 2015–2017, was linked to population-based health care data from the Estonian Health Insurance Fund. We calculated 14- and 30-day mortality after SACT and used a composite measure of intensity of care, comprised from the following: emergency department visit, admission to hospital, admission to intensive care unit, receipt of radiotherapy or systemic treatment.

Results: The median overall survival (OS) of patients who received at least one cycle of SACT (n = 489) was 9.1 months and in patients with no-SACT (n = 289) 1.3 months (hazard ratio [HR]=4.23, 95% CI=3.60-5.00). In the SACT group 6.7% and 14.7% of patients died within 14 days and 30 days after the last cycle, respectively. During the final 30 days of life, intensive EOL care was received by 69.9% of the SACT patients and 43.7% of the no-SACT patients (p < 0.001). Among SACT patients, sepsis, bacterial infection and/or neutropenia had a significant adverse effect on survival (HR=1.7, 95% CI=1.3-2.21, p < 0.001), whereas the use of the granulocyte colony stimulating growth factor reduced the risk of death (HR= 0.71, 95% CI=0.54-0.92, p = 0.011).

Conclusions: Significant proportions of patients with advanced lung cancer continue to receive intensive care near death. Our results highlight that neutropenia and infectious complications are still the primary cause of early SACT-related death.

Background

The intensity of treatment towards the end of life (EOL) has been suggested as one of the factors most affecting quality of life (QoL) in patients with advanced cancer [1-2]. Intensive care at the EOL is variably defined in literature. In 2003, Earle and colleagues were first to identify several markers of potentially overly aggressive EOL cancer care, later several studies supported these conclusions [3-5]. The internationally recognised intensity of care and quality of EOL care indicators in oncology are: intensive use of systemic anti-cancer treatment (SACT), low rates of hospice use, ED visits, hospitalisations and admissions to ICU; all measures occurring within 14 or 30 days of death [6-8]. These service-based indicators could easily be applied to existing administrative data to assess the utilisation of health care services at the EOL retrospectively.

ASCO’s expert panel for the “Choosing Wisely” campaign identified the use of chemotherapy with unknown benefits and in patients with poor performance status as the most widespread unnecessary practice in oncology [9]. Studies have reported that 5–22% of patients with advanced stage cancer received SACT within two weeks of death and up to 55% in the last month of life [10-11]. Early post-treatment mortality may be associated with SACT-related toxicity. Previous studies assessing
chemotherapy use at the EOL, however, have not always been able to discriminate between treatment-related and cancer-related mortality.

Despite recent developments in immunotherapy, conventional chemotherapy remains the cornerstone of the treatment of advanced stage lung cancer. Neutropenia and infectious complications are common and potentially life-threatening adverse effects of chemotherapy. As shown in the recent study by Whitney et al, the most common diagnoses resulting in unplanned hospitalisations through ED visits included infection or fever, and among patients with different solid tumours the rates were highest for lung cancer, with 5.2% of all cancer-related hospitalisations being related to neutropenia or fever in the US [12-13].

In Estonia, approximately 800 people annually are newly diagnosed with lung cancer [14]. In the current study, we aimed to characterise EOL care, health care intensity in the final 30 days of life and SACT-related mortality with an emphasis on infectious complications in patients with advanced stage lung cancer based on routine clinical data from the North Estonia Medical Centre's Thoracic Oncology Database. The Estonian Cancer Registry has been collecting data on cancer incidence and mortality since 1968, but in regard to anti-cancer treatment only surgery is captured. Particularly, data on palliative care in Estonia are lacking. We provide data that will inform oncologists and policymakers of the limitations in lung cancer care and should help them plan interventions to improve the quality of care.

Methods

Study cohort

This is a retrospective analysis of the health care data of patients with lung cancer treated at the North Estonia Medical Centre between 1 January 2015 and 31 December 2017. The North Estonia Medical Centre is the single provider of all types of oncology services for a population of 800 000, and its Thoracic Oncology Database has covered all patients with lung cancer since 2015. During the study period, a multidisciplinary tumour board had confirmed treatment decisions of 1485 patients with lung cancer (Figure 1). To identify the impact of palliative SACT, we excluded lung cancer patients with local disease whose primary treatment was either surgery or radiotherapy, irrespective of whether this was combined with SACT. This cohort contained 778 patients: 489 received SACT (SACT group) and 289 were not eligible to receive SACT (no-SACT group). The study was approved by the Tallinn Ethics Committee for Medical Research (no. 1972).

Data Sources

Patient characteristics such as age, gender, stage, date of biopsy if performed, histology, disease status as newly diagnosed or recurrent and date of treatment decision were extracted from the Thoracic Oncology Database. The patient’s national identification code from the Thoracic Oncology Database was linked to the electronic database of billing data of the Estonian Health Insurance Fund. This database incorporates detailed data on all medical services used during a hospital stay and any out-patient visits, including each cycle of SACT provided. To calculate the chemotherapy receipt within the last 14 and 30
days of life, the date of last cycle of SACT was linked to the date of death. The electronic data of patients who died within 14 and 30 days after the last cycle of SACT were reviewed in detail by two authors independently, and the probable cause of death related to progression and SACT-related toxicity such as sepsis, bacterial infection and neutropenia was identified. Data on the death, if applicable, was retrieved from the National Death Registry. The data cut-off date was 31 July 2018.

Outcome measures

The outcome measures to be assessed in this study were chosen on the basis of previous research. We analysed health care utilisation and the circumstances of death, calculated 14- and 30-day mortality after SACT and used a composite measure of intensity of care, comprised from the following: emergency department visit, admission to hospital, admission to ICU, receipt of radiotherapy or systemic treatment (except no-SACT). The frequency of infectious complications (sepsis, bacterial infections and/or neutropenia) and the use of the granulocyte colony stimulating growth factor (GCS-GF) and/or radiotherapy was re-calculated for the period of 14 days or 30 days after the last SACT. For comorbidities in the whole cohort, we used only major diagnoses affecting chemotherapy administration such as diabetes (type 1 and 2), atrial fibrillation, cardiovascular disease (cardiac and peripheral vascular disease), and chronic obstructive pulmonary disease.

Statistical analysis

To describe the baseline characteristics and background data of the study population and health care use at the EOL, frequencies and percentages were used for categorical data and mean values with standard deviations (SD) or median values with quartiles (Q25-Q75) for numeric data. To compare the characteristics of SACT and no-SACT patients and SACT patients who died within 14 days and 30 days after their last treatment, the Mann-Whitney U test (numeric variables), Fisher test or z-test (categorical variables) was used. Overall survival (OS) was calculated from the treatment decision date. We used Kaplan Meier estimates to evaluate the survival of patients with SACT versus those with no-SACT. A multivariate Cox proportional hazards model was used to evaluate the effect of chemotherapy, gender, age, stage, disease status, histology, comorbidities and infectious complications on survival among patients with SACT. The same variables were studied as potential predictors of intensive EOL care; statistical significance was tested with the z-test. Multivariable logistic regression models were constructed to determine factors associated with intensive EOL care. All significance tests were two sided with an α-level of 0.05. Bonferroni corrections were used on multiple comparisons. Patients were censored at the time of the data cut-off date and assumed alive if no national death date was given. All analyses were conducted using Stata 14.2 software.

Results

Characteristics of the study population and treatment patterns
A retrospective cohort of patients with lung cancer, who were treated at the North Estonia Medical Centre during the study period from 2015–2017, was assembled using the institutional Thoracic Oncology Database (Figure 1). Patients’ baseline characteristics are presented in Table 1. The patients in the SACT group were younger than those who did not receive SACT. A biopsy was performed in almost all patients of the SACT group, whereas it was not possible in 23% of no-SACT patients. As a result, no histology data was available for 47% of no-SACT patients vs 15% of SACT patients. The patients in the no-SACT group had more cardiac comorbidities, whereas the patients in the SACT group had more treatment-related complications. In the SACT group, the first cycle of SACT was administered on average 24 days after the treatment decision. The mean number of SACT courses was 6.3 (median 4), and the patients with adenocarcinoma received twice as many SACT courses compared with squamous and small-cell lung cancer patients (Supplemental Table 1).

Table 1. Baseline and clinical characteristics of the study population.
|                                | SACT (n=489) | no-SACT (n=289) | p      |
|--------------------------------|--------------|-----------------|--------|
| **Male**                       | 338 (69.1%)  | 219 (75.8%)     | 0.049  |
| **Female**                     | 151 (30.9%)  | 70 (24.2%)      |        |
| **Age at the time of MDT**     |              |                 |        |
| ≤ 49.9                         | 20 (4.1%)    | 5 (1.7%)        | < 0.001|
| 50 – 64.9                      | 194 (39.7%)  | 45 (15.6%)      |        |
| 65 – 74.9                      | 183 (37.4%)  | 115 (39.8%)     |        |
| ≥ 75                           | 92 (18.8%)   | 124 (42.9%)     |        |
| median (Q25–Q75)               | 66 (60–73)   | 73 (67–79)      |        |
| **Biopsy**                     |              |                 |        |
| Yes                            | 483 (98.8%)  | 222 (76.8%)     | < 0.0001|
| No                             | 6 (1.2%)     | 67 (23.2%)      |        |
| **Histology**                  |              |                 |        |
| adenocarcinoma                 | 168 (34.4%)  | 45 (15.6%)      | < 0.001|
| squamous                       | 124 (25.4%)  | 69 (23.9%)      |        |
| small cell                     | 125 (25.6%)  | 40 (13.8%)      |        |
| Other/no malignancy/no histology | 72 (14.7%) | 135 (46.7%) |       |
| **Stage**                      |              |                 |        |
| II                             | 2 (0.4%)     | 0 (0%)          | 0.74   |
| III                            | 137 (28.0%)  | 80 (27.7%)      |        |
| IV                             | 350 (71.6%)  | 209 (72.3%)     |        |
| **Newly diagnosed**            | 390 (79.8%)  | 252 (87.2%)     | 0.008  |
| **Recurrence**                 | 99 (20.2%)   | 37 (12.8%)      |        |
| **Time from biopsy to MDT (days)** |          |                 |        |
| median (Q25–Q75)               | 12 (2–27)    | 8 (0–18)        | 0.0005 |
| (min–max)                      | (0–3555)     | (0–3240)        |        |
| **Palliative radiotherapy**    |              |                 |        |
| ≤ 3 months before MDT          | 14 (2.9%)    | 6 (2.1%)        | 0.64   |
| since MDT                      | 181 (37.0%)  | 16 (5.5%)       | < 0.001|
| **Comorbidities**              |              |                 |        |
| ≤ 3 months before MDT          |              |                 |        |
| Sepsis                         | 1 (0.2%)     | 2 (0.7%)        | 0.56   |
| Bacterial infection             | 0 (0%)       | 4 (1.4%)        | 0.019  |
| Drug-related neutropenia       | 0 (0%)       | 0 (0%)          |        |
| Diabetes                       | 54 (11.0%)   | 42 (14.5%)      | 0.176  |
| Atrial fibrillation             | 49 (10.0%)   | 53 (18.3%)      | 0.001  |
| Cardiovascular disease          | 266 (54.4%)  | 187 (64.7%)     | 0.005  |
| COPD                           | 107 (21.9%)  | 85 (29.4%)      | 0.02   |
| since MDT                       |              |                 |        |
| Sepsis                         | 52 (10.6%)   | 16 (5.5%)       | 0.018  |
| Bacterial infection             | 44 (9.0%)    | 3 (1.0%)        | < 0.001|
| Drug-related neutropenia       | 34 (7.0%)    | 0 (0%)          | < 0.001|
| COPD                           | 109 (22.3%)  | 13 (4.5%)       | 0.001  |

Abbreviations: MDT, multidisciplinary tumour board; SACT, systemic anti-cancer treatment; Q, quantile; COPD, chronic obstructive pulmonary disease.

**Overall survival and location of death**
By the study cut-off date, 77% of SACT patients had died compared with 96% of no-SACT patients (Table 2). The median OS of no-SACT patients was 1.3 months and in patients who received at least one cycle of SACT 9.1 months (hazard ratio [HR]=4.23, 95% CI=3.60-5.00, p<0.001), (Figure 2, Panel A). The OS of patients with adenocarcinoma histology was significantly longer than all other histologies (median OS 13.3 vs 8.1 months, HR=0.61, 95% CI=0.49-0.76, p<0.001), but there was no difference in the OS between histological subtypes in the no-SACT group (p=0.951), (Figure 2, Panel B). Among the patients who died during the study period, only 21% of patients in the no-SACT group died in a hospital (acute care or nursing hospital), whereas 38% of the SACT group deaths occurred in an acute care hospital and 24% in a nursing hospital (Table 2). In total, 22% of patients in the SACT group died in the hospital after they had been admitted via emergency department. In the SACT group, 77% of the deaths had occurred at the data cut-off date with a median survival of 75 days after the last cycle of SACT (Supplemental Table 1).

Table 2. Mortality and location of death in patients with and without systemic anti-cancer treatment.

|                                             | SACT Yes (N=489) | No-SACT (N=289) |
|---------------------------------------------|------------------|-----------------|
| Died ≤ 14 days since MDT, N (%)              | 4 (0.8)          | 68 (23.5)       |
| Died ≤ 30 days since MDT, N (%)              | 12 (2.5)         | 118 (40.8)      |
| Died ≤ 30 days since last cycle, N (%)       | 72 (14.7)        | NA              |
| Died at data cut off, N (%)                  | 376 (76.9)       | 279 (96.5)      |
| Place of death                               |                  |                 |
| Acute care hospital*                         | 144 (38.3)       | 41 (14.2)       |
| * Died at hospital when the date of last claim was the date of death plus 1 day. ** Died at hospital through ED visit when the last claim started with the date of ED claim. 9 patients in the SC arm and 30 patients in the SACT arm died on same or next day as ED visit. Abbreviations: SACT, systemic anti-cancer treatment; ED, emergency department. |
| ** ED visit of them**                        | 82 (21.8)        | 28 (9.7)        |
| Nursing hospital                             | 90 (23.9)        | 20 (6.9)        |
| Out-of-hospital                              | 142 (37.8)       | 218 (75.4)      |

Intensity of care at the EOL

Any one of the following outcomes – hospitalisation, ED visit, ICU admission, radiotherapy or SACT (except no-SACT) – occurred 70% in the SACT group and 44% in the no-SACT group during the final 30 days of life (Table 3). 0.8% and 2.5% of SACT patients had died within 14 and 30 days after the treatment decision, respectively, compared with the 24% and 41% in the no-SACT group (Table 2). Only 22 (7.6%) patients in the no-SACT group received palliative radiotherapy, seven (2.5% of deceased) of which in the last 30 days of life (Table 2). In total, 195 (39.9%) patients in the SACT group received radiotherapy, but only 12 patients (3.2%) received radiotherapy within the final 30 days of life. The 63 patients who received only one course of SACT had a similar OS to patients with no-SACT (HR=0.97, 95% CI=0.73-1.28, p=0.8), (Figure 2, Panel A), indicating no benefit from systemic treatment in these patients. In addition, 37 patients died within 30 days after the last cycle of SACT due to disease progression (Table 4), comprising
a total of 100 patients (20% of 489 patients) who did not benefit from SACT and illustrating potential overtreatment. Intensive EOL care in the last 30 days of life is more probable among patients in the SACT group (odds ratio [OR]=3.58, 95% CI=2.54-5.04, p<0.001), especially in those with a stage IV disease (OR=1.89, 95% CI=1.31-2.71, p=0.001).

Table 3. The intensity of care in the final 30 days of life in deceased patients.

| Care measure          | SACT (N=376) | No-SACT (N=279) | p *** |
|-----------------------|--------------|-----------------|------|
|                       | N   | %   | N   | %   |      |
| Any hospitalization   | 237 | 63.0| 110 | 39.4| < 0.001|
| Hospitalizations*     | 186 | 49.5| 99  | 35.5| < 0.001|
| Sepsis                | 42  | 11.2| 11  | 3.9 | 0.0064|
| Bacterial infection   | 14  | 3.7 | 1   | 0.4 | 0.0352|
| Neutropenia           | 11  | 2.9 | 0   | 0.0 | -    |
| ED visit              | 187 | 49.7| 87  | 31.2| < 0.001|
| ICU admission         | 49  | 13.0| 36  | 12.9| 0.99  |
| SACT                  | 72  | 19.1| -   | -   | -    |
| RT                    | 12  | 3.2 | 7   | 2.5 | 0.99  |
| Composite of measures**| 263 | 69.9| 122 | 43.7| < 0.001|
| All 5 (SC 4)          | 0   | 0.0 | 0   | 0.0 | -    |
| None                  | 113 | 30.1| 157 | 56.3| < 0.001|

* Hospitalizations without sepsis, bacterial infection or neutropenia. ** Any of the following outcomes: hospitalization, ED visit, ICU admission, SACT (except SC), or RT. *** Tested by z-test with Bonferroni correction. Abbreviations: SACT, systemic anti-cancer treatment; ED, emergency department; ICU, intensive care unit; RT, radiotherapy.

Table 4. Cause of death in patients who died within 14 days or during 15–30 days of systemic anti-cancer treatment.

| Characteristics                          | ≤ 14 days | 15-30 days | Total | p    |
|------------------------------------------|-----------|------------|-------|------|
| Died after 1st SACT cycle, N (%)         | 16 (48.5) | 9 (23.1)   | 25 (34.7)| 0.03 |
| Total SACT cycles (median, range)        | 2 (1-13)  | 4 (1-17)   | 3 (1-17)| 0.06 |
| NEU before last cycle, N (%)             | 5 (15.2)  | 1 (2.6)    | 6 (8.3) | 0.09 |
| GCS-GF*                                  | 3 (9)     | 3 (7.7)    | 6 (8.3) | 1    |
| NEU/PAN after last cycle                 | 9 (27.3)  | 5 (12.8)   | 14 (19.4)| 0.145|
| ICU before death                         | 15 (45.5) | 5 (12.8)   | 20 (27.8)| 0.003|
| Cause of death, N (%)                    |           |            |       |      |
| CV                                       | 3 (9.1)   | 3 (7.7)    | 6 (8.3) |      |
| INF                                      | 9 (27.3)  | 7 (18)     | 16 (22.2)| 0.09 |
| PD                                       | 13 (39.4) | 26 (66.7)  | 39 (54.2)|      |
| SUDDEN                                   | 8 (24.2)  | 3 (7.7)    | 11 (15.3)|      |

* GCS-GF primary prophylaxis before last cycle. Values in bold are significant at p < 0.05. Abbreviations: SACT, systemic anti-cancer treatment; NEU, neutropenia; GCS-GF, granulocyte colony stimulating growth factor; PAN, pancytopenia; ICU, intensive care unit admission; CV,
cardiovascular; INF, infection; PD, progression; SUDDEN, sudden death or unknown with good performance status at the time of last SACT.

**SACT-related toxicity and 14- and 30-day mortality**

The SACT patients received on average 6.3 (median 4) cycles of systemic chemotherapy and the median duration of treatment was 78 days, except for patients with adenocarcinoma (on average 9 courses over 135 days; \( p < 0.001 \)), (Supplemental Table 1). In the SACT group, 10.6% and 7.0% of patients developed at least one case of sepsis or neutropenia, respectively (Table 1). Approximately 30% of patients received GCS-GF support, but we were not able to differentiate between primary and secondary prophylaxis or the treatment of neutropenia (Supplemental Table 2). In the SACT group, 33 patients (6.7%) died within 14 days and 72 patients (14.7%) within 30 days of the last SACT cycle. 11.2% of the deceased were hospitalised due to sepsis and 2.9% had neutropenia in the final 30 days (Table 3). In total, 46% of early deaths (in 14 days) occurred after the first cycle of SACT. 22.2%, 6.9% and 11.1% of patients with 30-day mortality after SACT developed sepsis, bacterial infection or drug-related neutropenia, respectively, whereas these infectious complications developed in less than 10% of patients who died more than 30 days after the last cycle of SACT (Supplemental Table 2). These differences were statistically significant in the univariate analysis. In the multivariate Cox proportional hazard models, male gender, age younger than 69 years, histology other than adenocarcinoma and concomitant sepsis, bacterial infection or neutropenia had a significant adverse impact on survival, whereas GCS-GF use was associated with better survival (Table 5). We then aimed to identify the cause of death in patients with early SACT-related mortality. Patients who died within 14 days after SACT were more likely to die after the first cycle \( (p = 0.03) \), to have one episode of neutropenia before the last cycle \( (15.2\% \ vs \ 2.6\%, \ p = 0.09) \), to develop neutropenia or pancytopenia after the last cycle \( (27.3\% \ vs \ 12.8\%, \ p=0.145) \), to be admitted to the ICU before death \( (p=0.003) \) and to die due to infection \( (p=0.09) \), (Table 4).

**Table 5. Multivariate Cox proportional hazards models of survival among patients who received systemic anti-cancer treatment.**
| Characteristic               | Unadjusted HR (95%CI) | Adjusted* HR (95%CI) | Adjusted p |
|-----------------------------|-----------------------|----------------------|------------|
| **Gender**                  |                       |                      |            |
| Female                      | 1                     | 1                    | .014       |
| Male                        | 1.56 (1.24–1.96)      | 1.36 (1.06–1.73)     |            |
| **Age**                     |                       |                      |            |
| ≤ 49                        | 1                     | 1                    |            |
| 50-59                       | 2.11 (1.14–3.89)      | 2.17 (1.17–4.03)     | .014       |
| 60-69                       | 1.80 (1.00–3.25)      | 1.91 (1.05–3.49)     | .035       |
| 70-79                       | 1.45 (0.80–2.64)      | 1.60 (0.87–2.895)    | .131       |
| 80 ≥                        | 1.67 (0.84–3.31)      | 1.92 (0.95–3.87)     | .067       |
| **Comorbidities (yes vs no)**|                      |                      |            |
| Diabetes                    | 0.94 (0.71–1.26)      | 1.12 (0.83–1.52)     | .465       |
| Cardiovascular              | 0.84 (1.05–1.43)      | 0.91 (0.70–1.17)     | .457       |
| Atrial fibrillation         | 1.00 (0.78–1.30)      | 0.96 (0.72–1.27)     | .761       |
| Sepsis/infection/Neutropenia| 1.53 (1.20–1.95)      | 1.70 (1.30–2.21)     | < .001     |
| COPD                        | 0.99 (0.80–1.25)      | 0.89 (0.71–1.12)     | .315       |
| **Disease status**          |                       |                      |            |
| Newly diagnosed             | 1.14 (0.88–1.47)      | 1.28 (0.97–1.69)     | .091       |
| Recurrence                  | 1                     | 1                    |            |
| **Stage**                   |                       |                      |            |
| II                          | 0.87 (0.21–3.52)      | 0.94 (0.22–4.00)     | .935       |
| III                         | 1                     | 1                    |            |
| IV                          | 0.96 (0.76–1.20)      | 1.16 (0.91–1.47)     | .229       |
| **Histology**               |                       |                      |            |
| Adenocarcinoma              | 1                     | 1                    |            |
| Squamous                    | 1.58 (1.21–2.06)      | 1.52 (1.13–2.04)     | .006       |
| SCLC                        | 1.63 (1.19–2.24)      | 1.37 (0.99–1.91)     | .06        |
| Other                       | 1.70 (1.29–2.24)      | 1.82 (1.34–2.46)     | < .001     |
| **Other cancer treatment**  |                       |                      |            |
| GCS-GF                      | 0.88 (0.70–1.12)      | 0.71 (0.54–0.92)     | .011       |
| Radiotherapy                | 1.02 (0.83–1.26)      | 0.88 (0.71–1.09)     | .246       |

* Adjusted on all patient and disease related variables in the table. Values in bold are significant at p < .05. HR, hazard ratio; CI, confidence interval; p, probability; COPD, chronic obstructive pulmonary disease; SCLC, small cell lung cancer; GCS-GF, granulocyte colony stimulating growth factor.

**Discussion**

To our knowledge, this is the first study to evaluate EOL cancer care in Estonia and in Eastern Europe. Our results confirm that a significant proportion of patients with advanced lung cancer continue to receive intensive care near death. Nearly 15% of patients in the current study died within 30 days after the last cycle of SACT. Infectious complications with neutropenia had significant adverse effects on survival. These findings are particularly important, as chemotherapy in combination with immunotherapy is the currently recommended first line of treatment in most patients with advanced lung cancer.
Patients with a poor performance status do not benefit from chemotherapy [9,15]. In our study, patients with the treatment decision no-SACT had a poor prognosis with a median OS of 1.3 months. Due to the lack of EOL services, they were frequently hospitalised through ED visits near death. 78% of the deceased in the no-SACT group died outside hospital (acute or nursing hospital). There was no possibility to collect data on care and costs paid by a family, including home-based care. However, our findings indicate very limited provision of organised health care services to patients deemed ineligible for active oncological treatment. It is well recognised that EOL care is a subject for considerable policy differences, which also exist among developed countries. For instance, in the US and the Netherlands, the lowest proportion of cancer patients died in acute care hospitals (less than 30%), whereas 77% of cancer patients in France die in hospitals [16,17]. Previous studies have not reported EOL data depending on patients’ eligibility for active oncological treatment; however, this likely affects who provides EOL care and how it is provided. Our study demonstrated that there is an urgent need to increase EOL supportive care services in Estonia, particularly for patients not eligible for active treatment.

The median OS of patients in this study who received at least one cycle of SACT was 9.1 months. One-third of patients who opted for SACT accounted for potential overtreatment, including patients who received only one cycle of SACT, patients who died of progression after receiving SACT in the final 30 days and patients who never received systemic treatment despite the decision. Timely access to SACT is an important aspect of cancer care, particularly affecting patients with high disease and symptom burden. The median time from the diagnosis to the start of systemic treatment was approximately one month in the current study. Prioritisation of patients eligible for SACT is necessary to reduce delays in treatment initiation and improve outcome.

We chose previously reported indicators of the intensity of cancer care relevant to adult patients with solid tumours [3-8]. A composite measure for intensive EOL care was received by 70% of the deceased SACT patients and 44% of the no-SACT patients in the current study. Moreover, 66% of the total 489 SACT patients had at least one ED visit after the initiation of SACT, including 30 patients who died on the same or next day as the ED visit. Our findings are in line with those from Canada, where 62% of patients with lung cancer had at least one ED visit in the last 30 days [17]. In the US, ICU admissions near death were twice as high as those in six other developed countries, with 27% of adult cancer patients being admitted to the ICU in the last 30 days [17]. In our study, 13% of patients in both the SACT and no-SACT groups experienced ICU admission. We found no evident pattern between patient characteristics and the likelihood of receiving intensive EOL care. Future research should focus on causes leading to ED visits and whether these could be avoided by improving palliative and hospice care.

Of the various intensive EOL care measures, the use of chemotherapy near death has been studied most extensively. Chemotherapy use in the last 30 days of life ranged from 4.8% (Norway) to 10.6% (US) and 12.7% (Belgium) [17]. Among various solid tumours, patients with lung cancer were more likely to receive chemotherapy at the EOL [18]. At the data cut-off date, 19% of the deceased patients in our study had received SACT in the final 30 days of life, similar to the rate reported in France [16]. In England, 30-day mortality after SACT was higher in patients with lung cancer compared to patients with breast cancer,
with a considerable difference in curative (3%) and palliative (10%) treatments [19]. Infectious complications were significant predictors for early SACT-related death and hospitalisations in our study (Supplemental Table 2). Among EOL hospitalisations, 11% were due to sepsis and 3% of patients had neutropenia. Patients who died within 14 days after SACT were more likely to die due to neutropenia and infection, whereas patients who died within 15-30 days after the last cycle of SACT were more likely to die of progressive disease. We demonstrated that sepsis, bacterial infection and/or neutropenia had a significant adverse effect on survival, whereas GCS-GF use reduced the risk of death. We were not able to differentiate whether the use of GCS-GF was primary or secondary prophylaxis. It has previously been shown that cancer-related neutropenia accounts for a substantial amount of the total cancer-related hospitalisation costs [20]. ASCO’s guideline for the management of neutropenia generally recommends primary prophylaxis when the risk of neutropenia is high (>20%) [21]. In recent decade, several biosimilar GCS-GF products have been approved in the EU and in rest of the world, making the use of neutropenia prophylaxis more cost-effective. Our findings suggest that a lower threshold for primary prophylaxis may be needed for lung cancer and also highlight the importance of SACT-related toxicity when studying the mortality at the EOL.

Our study has several limitations. Firstly, it was a single centre retrospective cohort study with a relatively small sample size. Secondly, our study was based on the data of health service use and we had no information on the performance status of patients. However, for those patients who died within 30 days after SACT, a detailed review of electronic medical records was conducted and the probable cause of death identified. The strengths of this study include: a) universal insurance coverage in Estonia, meaning our results capture all health care services provided to patients; b) systemic treatment of lung cancer for the whole population in the catchment area is delivered only in this specific cancer centre, thus the study cohort includes all cancer patients; c) homogenous population, eg patients with advanced lung cancer from the routine clinical database; d) homogenous systemic treatment, as ALK-inhibitors and immunotherapy were not reimbursed at the time of the study; e) most recent study period; f) the cause of death was evaluated through detailed review of electronic medical records.

Conclusions

A significant proportion of patients with advanced lung cancer continue to receive intensive care near death with a negative health impact. Our results reflect the patterns of the EOL care of lung cancer in Estonia, where the availability of palliative health care services and hospice care must be increased to improve resource use and patient-oriented care. Chemotherapy is the cornerstone of the treatment of advanced lung cancer, and our results illustrate that the careful selection of patients and a conservative use of SACT are important because neutropenia and infectious complications are still the primary causes of early SACT-related death.

Abbreviations

ED: Emergency Department
EOL: End of life
ICU: Intensive Care Unit
GCS-GF: Granulocyte colony stimulating growth factor
MDT: Multidisciplinary tumour board
OS: Overall survival
QoL: Quality of life
SACT: Systemic anti-cancer treatment

Declarations

Ethics approval and consent to participate
Tallinn Ethics Committee for Medical Research (no. 1972).

Consent for publication
Not applicable

Availability of data and material
Datasets analyzed are available from the corresponding author.

Competing interests
Authors have no conflicts of interests in regard to this publication.

Funding
Supported by the research grant from the North Estonia Medical Centre.

Authors’ contributions
KO contributed to the concept and design, collected and analysed data, wrote the main part of the manuscript. HP analysed the data, performed statistical analysis and contributed to the manuscript. KI collected the data, contributed to the data interpretation and manuscript writing. RAK contributed to the concept, interpretation of the data and manuscript writing.

All authors have read and approved the manuscript.

Acknowledgements
We thank Sirly Lätt from the Estonian Health Insurance Fund and Sirje Kaarna from the North Estonia Medical Centre for conducting the data linking.

References

[1] Dasch B, Kalies H, Feddersen B, Ruderer C, Hiddemann W, Bausewein C. Care of cancer patients at the end of life in a German university hospital: A retrospective observational study from 2014. PLoS One 2017;12:e0175124.

[2] Heikkilä R, Kaasa S. Chemotherapy in end-of-life care. Ann Oncol 2017;28:684–5.

[3] Earle CC, Park ER, Lai B, Weeks JC, Ayanian JZ, Block S. Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol 2003;21:1133–8.

[4] Earle CC, Landrum MB, Souza JM, et al. Aggressiveness of cancer care near the end of life: Is it a quality-of-care issue? J Clin Oncol 2008;26:3860-3866.

[5] Barbera L, Seow H, Sutradhar R, Chu A, Burge F, Fassbender K, et al. Quality Indicators of End-of-Life Care in Patients With Cancer: What Rate Is Right? J Oncol Pract 2015;11:e279–87.

[6] Kassam A, Sutradhar R, Widger K, et al. Predictors of and Trends in High-Intensity End-of-Life Care Among Children With Cancer: A Population-Based Study Using Health Services Data. J Clin Oncol 2017;35:236-242.

[7] Wang R, Zeidan AM, Halene S, et al. Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. J Clin Oncol 2017;35:3417-3424.

[8] Taylor JS, Rajan SS, Zhang N, et al. End-of-Life Racial and Ethnic Disparities Among Patients With Ovarian Cancer. J Clin Oncol 2017;35:1829-1835.

[9] Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, et al. American society of clinical oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology. J Clin Oncol 2012;30:1715–24.

[10] Ho TH, Barbera L, Saskin R, Lu H, Neville BA, Earle CC. Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol 2011;29:1587–91.

[11] Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733–42.

[12] Whitney RL, Bell JF, Tancredi DJ, Romano PS, Bold RJ, Wun T, et al. Unplanned Hospitalization Among Individuals With Cancer in the Year After Diagnosis. J Oncol Pract 2019;15:e20–9.
[13] Mor V, Wagner TH, Levy C, Ersek M, Miller C, Gidwani-marszowski R, et al. Association of Expanded VA Hospice Care With Aggressive Care and Cost for Veterans With Advanced Lung Cancer. JAMA Oncol. 2019 Jun 1;5(6):810-816.

[14] Innos K, Oselin K, Laisaar T, Aareleid T. Patterns of survival and surgical treatment in lung cancer patients in Estonia by histologic type and stage, 1996–2016. Acta Oncol 2019:1–8.

[15] Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, et al. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncol 2015;1:778.

[16] Rochigneux P, Raoul JL, Beaussant Y, Aubry R, Goldwasser F, Tournigand C, et al. Use of chemotherapy near the end of life: what factors matter? Ann Oncol 2017;28:809–17.

[17] Bekelman JE, Halpern SD, Blankart CR, Bynum JP, Cohen J, Fowler R, et al. Comparison of Site of Death, Health Care Utilization, and Hospital Expenditures for Patients Dying With Cancer in 7 Developed Countries. JAMA 2016;315:272.

[18] Fang P, Jagsi R, He W, Lei X, Campbell EG, Giordano SH, et al. Rising and Falling Trends in the Use of Chemotherapy and Targeted Therapy Near the End of Life in Older Patients With Cancer. J Clin Oncol 2019;37:1721–31.

[19] Wallington M, Saxon EB, Bomb M, Smittenaar R, Wickenden M, McPhail S, et al. 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study. Lancet Oncol 2016;17:1203–16.

[20] Tai E, Guy GP, Dunbar A, Richardson LC. Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012. J Oncol Pract 2017;13:e552–61.

[21] Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015;33:3199–212.

**Figures**
Figure 1

Flow chart of the study population. Abbreviations: SACT, systemic anti-cancer treatment.
Figure 2

Overall survival in the study population (panel A) according to number of SACT cycles and (panel B) histology. Abbreviations: SACT, systemic anti-cancer treatment; MDT, multidisciplinary tumour board; A, adenocarcinoma; O, all other histologies combined; SCLC, small cell lung cancer; SQ, squamous cell; HR, hazard ratio.
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementaldata.docx
- Tables.docx